Therapy-induced senescent tumor cell-derived extracellular vesicles promote colorectal cancer progression through SERPINE1-mediated NF-κB p65 nuclear translocation

Dan Zhang,Jian-Wei Zhang,Hui Xu,Xin Chen,Yu Gao,Huan-Gang Jiang,You Wang,Han Wu,Lei Yang,Wen-Bo Wang,Jing Dai,Ling Xia,Jin Peng,Fu-Xiang Zhou

DOI: https://doi.org/10.1186/s12943-024-01985-1

IF: 37.3

2024-04-06

Molecular Cancer

Abstract:Cellular senescence frequently occurs during anti-cancer treatment, and persistent senescent tumor cells (STCs) unfavorably promote tumor progression through paracrine secretion of the senescence-associated secretory phenotype (SASP). Extracellular vesicles (EVs) have recently emerged as a novel component of the SASP and primarily mediate the tumor-promoting effect of the SASP. Of note, the potential effect of EVs released from STCs on tumor progression remains largely unknown.

oncology,biochemistry & molecular biology

What problem does this paper attempt to address?

The paper aims to explore the mechanisms of therapy-induced senescence (TIS) in tumor cells and the extracellular vesicles (EVs) they release in the progression of colorectal cancer (CRC), and to evaluate the clinical prognostic significance of these changes.

Specifically, the study found:
1. Chemotherapy drugs and radiotherapy can significantly induce senescence in colorectal cancer cells, and this phenomenon has also been validated in patient tissue samples.
2. Therapy-induced senescent tumor cells (STCs) release more extracellular vesicles (EVs) compared to non-STCs, and these EVs can promote tumor progression both in vivo and in vitro.
3. The study revealed that EVs derived from STCs are rich in serpin family E member 1 (SERPINE1), and through the packaging of EVs, SERPINE1 is transported to recipient cells, where it binds to NF-κB p65, promoting its nuclear translocation, thereby activating the NF-κB signaling pathway and leading to tumor progression.
4. Using the specific inhibitor tiplaxtinin (TPX) to target and inhibit SERPINE1 can significantly weaken the pro-tumor effects of STC-derived EVs.
5. Patients with significantly increased expression of p16, p21, and SERPINE1 in CRC tissues after receiving anti-tumor therapy showed shorter disease-free survival (DFS) or progression-free survival (PFS).

In summary, this study not only provides in vivo evidence of the impact of TIS on tumor progression but also reveals the mechanism by which STCs promote CRC progression through the production of SERPINE1-rich EVs, and proposes the potential of targeting SERPINE1 as a therapeutic strategy.